Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Sorting Out Pandora's Box: Discerning the Dynamic Roles of Liver Microenvironment in Oncolytic Virus Therapy for Hepatocellular Carcinoma.

Altomonte J, Ebert O.

Front Oncol. 2014 Apr 22;4:85. doi: 10.3389/fonc.2014.00085. eCollection 2014. Review.

2.

Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.

Antoszczyk S, Spyra M, Mautner VF, Kurtz A, Stemmer-Rachamimov AO, Martuza RL, Rabkin SD.

Neuro Oncol. 2014 Aug;16(8):1057-66. doi: 10.1093/neuonc/not317. Epub 2014 Jan 26.

3.

Therapeutic response in patients with advanced malignancies treated with combined dendritic cell-activated T cell based immunotherapy and intensity-modulated radiotherapy.

Hasumi K, Aoki Y, Watanabe R, Hankey KG, Mann DL.

Cancers (Basel). 2011 Apr 28;3(2):2223-42. doi: 10.3390/cancers3022223.

4.
5.

NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors.

Alvarez-Breckenridge CA, Yu J, Price R, Wojton J, Pradarelli J, Mao H, Wei M, Wang Y, He S, Hardcastle J, Fernandez SA, Kaur B, Lawler SE, Vivier E, Mandelboim O, Moretta A, Caligiuri MA, Chiocca EA.

Nat Med. 2012 Dec;18(12):1827-34. doi: 10.1038/nm.3013. Epub 2012 Nov 25.

6.

Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.

Barnard Z, Wakimoto H, Zaupa C, Patel AP, Klehm J, Martuza RL, Rabkin SD, Curry WT Jr.

Neurosurgery. 2012 Sep;71(3):741-8; discussion 748. doi: 10.1227/NEU.0b013e318260fd73.

7.

Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses.

Altomonte J, Ebert O.

Microb Biotechnol. 2012 Mar;5(2):251-9. doi: 10.1111/j.1751-7915.2011.00296.x. Epub 2011 Sep 19. Review.

8.

Intelligent design: combination therapy with oncolytic viruses.

Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC, McCart JA.

Mol Ther. 2010 Feb;18(2):251-63. doi: 10.1038/mt.2009.283. Epub 2009 Dec 22. Review.

9.

Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL.

Huang JH, Zhang SN, Choi KJ, Choi IK, Kim JH, Lee MG, Kim H, Yun CO.

Mol Ther. 2010 Feb;18(2):264-74. doi: 10.1038/mt.2009.205. Epub 2009 Sep 8. Erratum in: Mol Ther. 2010 Feb;18(2):449. Lee, Mingul [corrected to Lee, Min-Geol].

10.

The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.

Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, Melcher AA, Vile RG.

Hum Gene Ther. 2009 Oct;20(10):1119-32. doi: 10.1089/hum.2009.135. Review.

11.

Design and application of oncolytic HSV vectors for glioblastoma therapy.

Grandi P, Peruzzi P, Reinhart B, Cohen JB, Chiocca EA, Glorioso JC.

Expert Rev Neurother. 2009 Apr;9(4):505-17. doi: 10.1586/ern.09.9. Review.

Supplemental Content

Support Center